Stage F4 CirrhosisCompensated Care Checklist
Section 4 • Compensated Stage F4 Care

Understanding MASH Cirrhosis: What Stage F4 Really Means

How years of silent metabolic inflammation build stage F4 bridging bands, why 'burnt-out' cirrhosis often loses its visible fat, and the six daily habits that keep compensated cirrhosis stable.

Straight Talk From a Fellow Patient

Here is a paradox that confuses patients every single week: by the time MASH reaches stage F4 cirrhosis, a scan or biopsy may suddenly show very little fat left in the liver! Doctors call this 'burnt-out' MASH cirrhosis — dense collagen scar bands remodel the blood vessels so hepatocytes stop storing fat droplets, which used to get mislabeled for decades as 'cryptogenic cirrhosis.'

If your cirrhosis is compensated — meaning no belly fluid, no variceal bleeding, no jaundice, and clear thinking — your #1 job is defending that stability like a hawk. Stop all alcohol, ditch NSAID painkillers, protect your leg and core muscle with daily protein and walking, and show up like clockwork every 6 months for your liver ultrasound.

Signs Your Cirrhosis Is Still Compensated

  • Normal bilirubin (no yellowing of eyes or dark tea-colored urine) and steady albumin/INR.
  • No ascites (abdominal fluid buildup), no variceal GI bleeding, and clear memory/sleep patterns.
  • Many compensated F4 patients work full-time, travel, exercise daily, and feel completely normal.

Why Platelets Drop First (The Spleen Clue)

  • When liver scar tissue stiffens, portal blood backs up slightly into the spleen.
  • A mildly enlarged spleen traps platelets, dropping your platelet count below 150,000/μL long before symptoms appear.
  • Tracking platelets alongside FibroScan kPa helps your hepatologist time preventive carvedilol accurately.
Relative clinical risk across liver fibrosis stages F0 through F4 cirrhosis
Why Protecting Compensated F4 Matters: Once scarring reaches F4 cirrhosis, preventing portal hypertension flares and catching liver nodules early are the single biggest drivers of multi-decade survival.

Inside Stage F4: How Architectural Remodeling Raises Portal Pressure

To make smart choices about stage F4 MASH cirrhosis, it helps to picture the plumbing inside your upper right abdomen. In a healthy liver, roughly a liter and a half of nutrient-rich blood flows every minute from your stomach, intestines, pancreas, and spleen into the portal vein. That blood glides through millions of microscopic liver channels called sinusoids — delicate vessels lined with tiny open pores (fenestrations) so hepatocytes can pull out sugars, fats, medications, and gut toxins at whisper-low pressure. Normally, the pressure drop across the liver — measured as the hepatic venous pressure gradient (HVPG) — sits calmly between 1 and 5 mmHg.

When silent metabolic steatohepatitis (MASH, formerly called NASH in older charts) smolders for 10 to 25 years, injured liver cells continuously wake up neighbor cells called hepatic stellate cells, turning them into tough scar-spinning myofibroblasts. Stage F4 cirrhosis marks three architectural changes happening together:

1. Fibrous Septa (Scar Bridges)

Broad ribbons of cross-linked Type I and III collagen link portal tracts to central veins, walling off normal lobules like concrete dividers poured across an open sponge.

2. Regenerative Nodules

Your surviving hepatocytes keep trying to heal! Trapped inside stiff collagen rings, they multiply into rounded islands (nodules) that gently compress adjacent microscopic veins.

3. Sinusoidal Capillarization

The tiny open pores lining liver sinusoids seal over with basement membrane, while stressed vessel walls make too little nitric oxide — tightening intrahepatic vessels like a pinched garden hose.

Combine stiff collagen walls with narrowed sinusoids and portal blood meets serious resistance. Once HVPG climbs to 10 mmHg or higher, hepatologists call it clinically significant portal hypertension (CSPH) — the quiet threshold where blood begins backing up into the spleen (trapping platelets) and seeking detour veins along the esophagus and stomach. Meanwhile, altered blood flow and portosystemic shunting starve nodules of the insulin signals that originally packed hepatocytes with fat droplets. That explains why "burnt-out" F4 MASH cirrhosis often shows almost zero fat on biopsy or CAP scan — a puzzle doctors mislabeled for decades as cryptogenic cirrhosis.

Baveno VII's "Rule of 5" (10–15–20–25 kPa + Platelets): Noninvasive Portal Pressure Staging

Years ago, the only way to check for portal hypertension was putting every cirrhosis patient under sedation for an upper endoscopy (EGD) or threading a pressure catheter into a neck vein. In 2022, the international Baveno VII consensus (and AASLD's 2024 portal hypertension guidance) gave patients and clinicians a simple, needle-free bedside yardstick called the Rule of 5. By pairing your FibroScan liver stiffness (kPa) with your routine platelet count, your hepatologist can estimate portal vein pressure in minutes:

FibroScan Stiffness TierPlatelet Count ContextWhat Baveno VII Tells You & Your Doctor
Under 10 kPaNormal (≥150,000/μL) and no other clinical signsRules out compensated advanced chronic liver disease (cACLD); 3-year risk of liver decompensation is below 1%. See Elastography Cutoffs.
10 to 15 kPaAny platelet levelSuggestive gray zone for advanced fibrosis/early cACLD — confirm trend with repeat fasting FibroScan, ELF blood score, or MR Elastography while treating metabolic drivers.
15 to 20 kPaPlatelets <110,000/μL (or ≥150,000/μL low-risk check)Confirms cACLD spectrum. If stiffness is <20 kPa and platelets stay above 150,000/μL, high-risk varices are very unlikely (<5%), safely sparing you a screening endoscopy! If 15–20 kPa with platelets <110,000/μL, CSPH probability exceeds 60%.
20 to 25 kPaPlatelets <150,000/μLHigh probability of CSPH (>60%): Portal pressure has likely crossed the 10 mmHg mark, warranting discussion of preventive portal-pressure therapy or endoscopic check.
25 kPa or HigherEven with normal platelets (adjusted for BMI ≥30 in MASH)Rules in CSPH (>90% specificity in non-obese MASH): Note that in MASH patients with BMI ≥30 kg/m², chest-wall thickness can nudge kPa upward, so specialists often apply the ANTICIPATE-NASH model (combining BMI, kPa, and platelets) to confirm true CSPH accurately.

Why Carvedilol Changed Compensated Care: Lessons From the Landmark PREDESCI Trial

What PREDESCI Proved (The Lancet, 2019)

For generations, doctors waited until large esophageal veins were on the verge of bleeding before prescribing beta-blockers. The randomized, double-blind PREDESCI trial tested treating compensated cirrhosis patients as soon as CSPH appeared — even before large varices formed.

Over a 3-year follow-up, lowering portal pressure cut first-time decompensation or death from 27% on placebo down to 16% (hazard ratio 0.51), driven above all by slashing first-time ascites more than 50% (9% vs. 20%).

Why Carvedilol Beats Older Beta-Blockers

Older drugs like propranolol and nadolol only block beta-1 and beta-2 receptors to reduce gut blood inflow. Carvedilol adds mild alpha-1 receptor vasodilation, gently relaxing constricted blood vessels right inside the scarred liver sinusoids so HVPG drops further at gentle doses (typically starting at 3.125 mg twice daily and stepping to 6.25 mg twice daily).

Home safety check: Keep a home blood-pressure cuff; let your clinic know if systolic BP dips below 90 mmHg or you feel lightheaded, and pause carvedilol under doctor guidance during acute infection, dehydration, or kidney injury.

Your 6-Point Every-Visit Checklist for Compensated MASH Cirrhosis

Care PillarSchedule / TargetWhy You Must Track It Yourself
1. Liver Cancer (HCC) SurveillanceLiver ultrasound + blood AFP every 6 months on the calendar — never skip.About 1%–3% of MASH cirrhosis patients per year develop hepatocellular carcinoma. Caught under 2 cm on a routine 6-month scan, HCC is highly curable; caught late by symptoms, options narrow fast.
2. Portal Hypertension Screening (Baveno VII)Track FibroScan stiffness (kPa) + platelet count; upper endoscopy (EGD) or carvedilol if clinically significant portal hypertension (CSPH).If liver stiffness is ≥25 kPa (or 20–25 kPa with platelets <150,000/μL), non-selective beta-blockers like carvedilol can cut the risk of first ascites or variceal bleeding nearly in half. See Ultrasound Elastography.
3. Muscle-Sparing Protein & Late-Evening Snack1.2–1.5 g protein/kg/day + a protein/complex-carb snack before bed; sodium ≤2,000 mg/day.A cirrhotic liver runs out of stored glycogen after just a few hours of sleep and starts burning your leg and core muscles (sarcopenia) unless you bridge the overnight fast. See Salt & Sodium.
4. Medication & OTC Safety AuditAvoid NSAIDs (ibuprofen, naproxen, high-dose aspirin); cap acetaminophen at ≤2,000 mg/day only if approved by your hepatologist.NSAIDs constrict kidney blood flow and irritate stomach/esophageal vessels in cirrhosis, risking sudden kidney injury or GI bleeding from a single bottle of pain relievers.
5. Vaccinations & Infection ShieldHepatitis A & B immunity check, annual flu, COVID-19, pneumococcal, and RSV/shingles per age.A viral hepatitis super-infection or severe pneumonia on top of F4 cirrhosis can tip a stable liver into acute-on-chronic decompensation overnight.
6. Zero Alcohol & Cardiometabolic ControlStrict zero alcohol; statin + diabetes/BP optimization + black coffee if tolerated.In F4 scarring, there is zero safe threshold for alcohol, while well-chosen statins (in Child-Pugh A) and diabetes control protect both your coronary arteries and portal pressure.

Why Every-6-Month Ultrasound + AFP Surveillance Matters (And When to Request Abbreviated MRI)

I tell every compensated F4 friend the same rule I live by myself: treat your 6-month liver scan like an airplane pre-flight check. Inside regenerative nodules, hepatocytes divide faster than normal to replace injured cells, which raises the yearly chance of a rogue cell forming hepatocellular carcinoma (HCC) to roughly 1% to 3% per year. Because the inside of your liver has zero pain nerves, an early 1.5 cm nodule feels exactly like a completely healthy Tuesday — yet liver tumors double in volume roughly every 4 to 6 months. That tumor-doubling clock is the exact reason AASLD guidelines set surveillance at every 6 months (not once a year), pairing an abdominal ultrasound with a blood draw for alpha-fetoprotein (AFP).

Crucial self-advocacy pearl for MASH cirrhosis: Ultrasound waves struggle to penetrate deep abdominal wall tissue, rib shadows, or coarse cirrhotic liver texture. Modern radiology reports now include an ultrasound Visualization Score (LI-RADS US VIS-A = minimal limitation, VIS-B = moderate, VIS-C = severe limitation). Open your patient portal and read the bottom lines of your ultrasound report! If the radiologist notes 'severely limited visualization' (VIS-C) due to body habitus or coarse echotexture, ultrasound alone can miss small early nodules — ask your hepatologist whether alternating or replacing ultrasound with a fast 15-minute abbreviated contrast MRI (AMRI) or multiphase CT is safer for your body.

Safe Exercise & Beating "Accelerated Overnight Starvation" in Compensated F4

Why Your Muscles Are Your Second Liver

Healthy livers store a generous tank of glycogen sugar to feed your brain while you sleep. A scarred F4 liver holds a much smaller tank — so after just 8 to 10 hours of overnight fasting, your body enters the same muscle-burning state a non-cirrhotic adult only hits after 36 to 72 hours of starvation!

  • Never practice prolonged intermittent fasting (like 16:8 or 24-hour fasts) once you have F4 cirrhosis — skipping breakfast eats away skeletal muscle that your body relies on to detoxify ammonia.
  • Eat a bedtime snack every night: Aim for ~15–20 g protein + ~30–50 g slow carbs 30–60 minutes before sleep (plain Greek yogurt with berries and walnuts, oatmeal made with milk/soy milk, or peanut butter on whole-grain toast). See our Mediterranean Diet Guide.

How to Exercise Safely With Portal Hypertension

Clinical trials in compensated cirrhosis show that regular aerobic + resistance exercise lowers portal pressure (HVPG) by ~1.5 to 2.5 mmHg, improves insulin sensitivity, and reverses frailty without triggering bleeding when varices are properly managed:

  • Daily movement target: Build gradually toward 150 minutes/week of brisk walking, cycling, swimming, or water aerobics.
  • Smart strength work (2–3 days/week): Use resistance bands, light-to-moderate dumbbells, sit-to-stand squats, and step-ups — exhaling smoothly on every lift.
  • One caution: Avoid maximal heavy powerlifting or holding your breath while straining (the Valsalva maneuver), which spikes pressure inside esophageal veins; if you have known varices, make sure carvedilol or banding is in place first.

Common Questions Patients & Families Ask

Why did my FibroScan CAP fat number drop even though my kPa stiffness climbed into F4?

That drop in liver fat is classic 'burnt-out' MASH cirrhosis, not sudden fat healing. When fibrous septa and capillarized sinusoids reroute microscopic portal blood flow, regenerating hepatocyte nodules lose exposure to high portal insulin concentrations and shift away from storing triglyceride droplets. Always judge stage F4 progress by your stiffness trend (kPa or MRE), platelet stability, albumin, and clinical status — never by CAP fat disappearance alone.

If my FibroScan + platelets show clinically significant portal hypertension and I start carvedilol, do I still need an endoscopy?

Under Baveno VII and 2024 AASLD portal hypertension guidance, compensated patients who tolerate therapeutic carvedilol typically do not need a routine screening upper endoscopy (EGD) just to look for varices, because carvedilol is already protecting against both bleeding and ascites. Your hepatologist will still order an EGD if you cannot tolerate beta-blockers (for instance, due to asthma, slow heart rate, or low blood pressure) or if warning symptoms arise.

Are Rezdiffra (resmetirom) or Wegovy (semaglutide) FDA-approved for stage F4 MASH cirrhosis?

Not yet for MASH cirrhosis specifically: current FDA accelerated approvals for Rezdiffra and Wegovy target non-cirrhotic MASH with F2–F3 fibrosis. However, dedicated Phase 3 cirrhosis trials (testing resmetirom in Child-Pugh A MASH cirrhosis, FGF21 analogs such as efruxifermin and pegozafermin, and carefully supervised incretin regimens) are actively underway, while GLP-1 therapies remain widely prescribed by specialists for coexisting Type 2 diabetes or obesity in compensated Child-Pugh A patients.

Why do hepatologists allow low-dose acetaminophen (Tylenol) in cirrhosis when the bottle warns about liver disease?

Overdosing on acetaminophen (over 4,000 mg/day, or mixing it with alcohol) damages any liver, which is why drugstore labels carry strict warnings. Yet at a doctor-approved cap of 2,000 mg/day or less in non-drinking cirrhosis patients, acetaminophen does not harm kidney blood flow or erode stomach veins — whereas over-the-counter NSAIDs (ibuprofen, naproxen, high-dose aspirin) can precipitate acute kidney failure or variceal bleeding after just a few tablets. Confirm your exact personal limit with your hepatologist.

Take Charge of Your Liver Health With the Steatotic Liver CommunityMembership is free. Get plain-spoken updates on MASLD & MASH treatments, live screening calculators, and patient advocacy.